BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:40:00 PM | Browse: 850 | Download: 814
Publication Name World Journal of Gastroenterology
Manuscript ID 4729
Country Australia
Received
2013-07-19 11:52
Peer-Review Started
2013-07-19 23:04
To Make the First Decision
2013-09-02 16:27
Return for Revision
2013-09-03 21:32
Revised
Second Decision
2013-10-21 17:35
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-10-22 07:41
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-11-28 12:10
Publish the Manuscript Online
2013-12-18 10:39
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Ophthalmologic complications of antiviral therapy in hepatitis C treatment
Manuscript Source Invited Manuscript
All Author List Roderick O'Day, Mark C Gillies and Golo Ahlenstiel
Funding Agency and Grant Number
Funding Agency Grant Number
National Health and Medical Research Council Project Grant APP1006759
Robert W. Storr Bequest to the Sydney Medical Foundation of the University of Sydney to Ahlenstiel G
Corresponding Author Dr. Golo Ahlenstiel, Department of Gastroenterology and Hepatology, Westmead Hospital, Hawkesbury Road, Westmead, NSW 2145, Australia. golo.ahlenstiel@sydney.edu.au
Key Words Interferon; Hepatitis C; Ocular complications; Retinopathy
Core Tip Interferon-associated retinopathy is usually a benign, transient phenomenon with no lasting impact on visual function. It occurs in approximately 30% of patients receiving antiviral therapy for chronic hepatitis C infection. The main risk factors for its development appear to be hypertension and diabetes. Unless a clear benefit to patients can be shown, a screening program for the development of interferon-associated retinopathy is not justified. No conclusive evidence exists for a causal link between it and the atypical adverse events of antiviral therapy, which tend to cause irreversible vision loss.
Publish Date 2013-12-18 10:39
Citation O’Day R, Gillies MC, Ahlenstiel G. Ophthalmologic complications of antiviral therapy in hepatitis C treatment. World J Gastroenterol 2013; 19(45): 8227-8237
URL http://www.wjgnet.com/1007-9327/full/v19/i45/8227.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i45.8227
Full Article (PDF) WJG-19-8227.pdf
Manuscript File 4729-Review.docx
Answering Reviewers 4729-Answering reviewers.pdf
Biostatistics Review Certificate Biostatistician_Review_Report_20130719053229.pdf
Copyright License Agreement 4729-Copyright assignment.pdf
Institutional Review Board Approval Form or Document Ethics_Committee_20130719053100.pdf
Peer-review Report 4729-Peer review(s).pdf
Scientific Editor Work List 4729-Scientific editor work list.doc